RU2017105596A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017105596A3 RU2017105596A3 RU2017105596A RU2017105596A RU2017105596A3 RU 2017105596 A3 RU2017105596 A3 RU 2017105596A3 RU 2017105596 A RU2017105596 A RU 2017105596A RU 2017105596 A RU2017105596 A RU 2017105596A RU 2017105596 A3 RU2017105596 A3 RU 2017105596A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034453P | 2014-08-07 | 2014-08-07 | |
| US62/034,453 | 2014-08-07 | ||
| PCT/US2015/044144 WO2016022883A1 (en) | 2014-08-07 | 2015-08-07 | Anti-ceramide antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017105596A RU2017105596A (ru) | 2018-09-07 |
| RU2017105596A3 true RU2017105596A3 (cg-RX-API-DMAC7.html) | 2019-04-17 |
| RU2717651C2 RU2717651C2 (ru) | 2020-03-24 |
Family
ID=55264608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017105596A RU2717651C2 (ru) | 2014-08-07 | 2015-08-07 | Антитела к церамиду |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10450385B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3177650B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6670297B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102296416B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107074949B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015300902B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2957415C (cg-RX-API-DMAC7.html) |
| IL (1) | IL250374B (cg-RX-API-DMAC7.html) |
| MX (1) | MX391141B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2717651C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201700787XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016022883A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017228474C1 (en) | 2016-03-04 | 2024-03-28 | Abmuno Therapeutics Llc | Antibodies to TIGIT |
| JP7264482B2 (ja) * | 2016-12-23 | 2023-04-25 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
| US20200362057A1 (en) | 2019-05-16 | 2020-11-19 | Snake River Bioscience, Inc. | Compositions and methods for the treatment of major depressive disorder |
| CN113906051B (zh) * | 2019-06-06 | 2025-06-06 | 北京加科思新药研发有限公司 | 对cd73具有特异性的结合分子及其用途 |
| US10975169B1 (en) * | 2019-09-27 | 2021-04-13 | Memorial Sloan Kettering Cancer Center | Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2 |
| KR102245082B1 (ko) * | 2020-02-14 | 2021-04-26 | 단국대학교 천안캠퍼스 산학협력단 | 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도 |
| WO2021188770A1 (en) * | 2020-03-18 | 2021-09-23 | Memorial Sloan Kettering Cancer Center | Anti-ceramide antibodies |
| EP4157875A1 (en) | 2020-06-02 | 2023-04-05 | Arcus Biosciences, Inc. | Antibodies to tigit |
| KR20230162788A (ko) * | 2021-03-16 | 2023-11-28 | 메모리얼 슬로안 케터링 캔서 센터 | 항-세라마이드 항체를 이용한 상처 치유 증진 |
| WO2024226646A2 (en) * | 2023-04-25 | 2024-10-31 | Memorial Sloan-Kettering Cancer Center | Dlk1 -targeting antibodies and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| JPH02128697A (ja) | 1988-11-09 | 1990-05-17 | Hoechst Japan Ltd | 抗フコシルセラミドモノクローナル抗体 |
| US7897753B2 (en) * | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA) |
| RU2310393C1 (ru) | 2006-02-16 | 2007-11-20 | ФГУ Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Российской Федерации | Способ прогнозирования обострений лепрозных невропатий у больных лепрой |
| JP5924863B2 (ja) | 2007-05-06 | 2016-05-25 | スローン ケタリング インスティテュート フォア キャンサー リサーチ | Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法 |
| US9163091B2 (en) | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US8410251B2 (en) * | 2008-06-20 | 2013-04-02 | National University Corporation Okayama University | Antibody against calcified globule and use of the same |
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| US9090679B2 (en) * | 2009-04-17 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
| FR2971250A1 (fr) * | 2011-02-07 | 2012-08-10 | Univ Nantes | Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese |
| KR101256351B1 (ko) | 2011-11-22 | 2013-04-19 | 김석진 | 필터 삽입공을 갖는 카메라 후드 |
| RU2631804C2 (ru) * | 2012-02-21 | 2017-09-26 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения или профилактики рака |
| EP2854850B1 (en) * | 2012-05-25 | 2021-05-26 | Sloan Kettering Institute For Cancer Research | Compositions for treating or preventing radiation disease and gi syndrome |
| WO2021188770A1 (en) * | 2020-03-18 | 2021-09-23 | Memorial Sloan Kettering Cancer Center | Anti-ceramide antibodies |
-
2015
- 2015-08-07 MX MX2017001686A patent/MX391141B/es unknown
- 2015-08-07 EP EP15830378.4A patent/EP3177650B1/en active Active
- 2015-08-07 US US15/502,162 patent/US10450385B2/en active Active
- 2015-08-07 KR KR1020177006255A patent/KR102296416B1/ko active Active
- 2015-08-07 RU RU2017105596A patent/RU2717651C2/ru active
- 2015-08-07 SG SG11201700787XA patent/SG11201700787XA/en unknown
- 2015-08-07 AU AU2015300902A patent/AU2015300902B2/en active Active
- 2015-08-07 JP JP2017506827A patent/JP6670297B2/ja active Active
- 2015-08-07 CN CN201580048151.7A patent/CN107074949B/zh active Active
- 2015-08-07 CA CA2957415A patent/CA2957415C/en active Active
- 2015-08-07 WO PCT/US2015/044144 patent/WO2016022883A1/en not_active Ceased
-
2017
- 2017-01-31 IL IL250374A patent/IL250374B/en active IP Right Grant
-
2019
- 2019-09-11 US US16/568,152 patent/US11447572B2/en active Active
-
2022
- 2022-08-15 US US17/887,952 patent/US20230416409A1/en not_active Abandoned
-
2024
- 2024-07-31 US US18/790,647 patent/US20250197524A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2957415A1 (en) | 2016-02-11 |
| MX391141B (es) | 2025-03-21 |
| US20190389970A1 (en) | 2019-12-26 |
| US10450385B2 (en) | 2019-10-22 |
| CN107074949B (zh) | 2021-06-15 |
| WO2016022883A1 (en) | 2016-02-11 |
| US20230416409A1 (en) | 2023-12-28 |
| SG11201700787XA (en) | 2017-02-27 |
| CN107074949A (zh) | 2017-08-18 |
| US11447572B2 (en) | 2022-09-20 |
| AU2015300902A1 (en) | 2017-03-02 |
| AU2015300902B2 (en) | 2020-05-28 |
| KR102296416B1 (ko) | 2021-09-01 |
| US20170335014A1 (en) | 2017-11-23 |
| IL250374B (en) | 2021-04-29 |
| EP3177650A4 (en) | 2018-01-03 |
| KR20170066327A (ko) | 2017-06-14 |
| MX2017001686A (es) | 2017-09-01 |
| JP6670297B2 (ja) | 2020-03-18 |
| JP2017527544A (ja) | 2017-09-21 |
| IL250374A0 (en) | 2017-03-30 |
| RU2717651C2 (ru) | 2020-03-24 |
| EP3177650B1 (en) | 2025-11-05 |
| NZ728981A (en) | 2024-03-22 |
| CA2957415C (en) | 2021-07-13 |
| BR112017002433A2 (pt) | 2017-11-28 |
| RU2017105596A (ru) | 2018-09-07 |
| EP3177650A1 (en) | 2017-06-14 |
| US20250197524A1 (en) | 2025-06-19 |